Literature DB >> 12413885

Interactions of opioid and chemokine receptors: oligomerization of mu, kappa, and delta with CCR5 on immune cells.

Shunji Suzuki1, Linda F Chuang, Peter Yau, Roy H Doi, Ronald Y Chuang.   

Abstract

Activation of opioid receptors by morphine was previously shown to specifically induce the expression of chemokine receptor CCR5, promoting simian AIDS virus entry and replication in immune cells. The present study was undertaken to determine whether these two structurally and functionally distinct G-protein-coupled receptors are in close proximity and form an oligomeric complex in the cell membrane so that the activation of one triggers the activity of the other. Both human CEM x174 and monkey lymphocytes were used in this study and gave similar results. Immunoprecipitation experiments showed that CCR5, but not CD4 nor Na(+)/H(+) exchanger, coprecipitates with all three subtypes (mu, delta, and kappa) of opioid receptors. A single protein band immunoreactive with antibodies against both the CCR5 and the opioid receptors was identified after electrophoresis on nondenaturing polyacrylamide gels. Chemical crosslinking experiments using glutaraldehyde or BS(3) indicate that these receptors are closely situated on the cell membrane with an intermolecular distance less than 11.4A. Functional studies revealed that a combination treatment of cells with morphine, an agonist for mu, and MIP-1beta, a ligand for CCR5, suppresses the inhibitory effect of MIP-1beta and increases the stimulatory effect of morphine on CCR5 expression. These results suggest that oligomerization of chemokine receptor CCR5 and opioid receptors on the cell membrane of human or monkey lymphocytes may modulate receptor functions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12413885     DOI: 10.1006/excr.2002.5638

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  46 in total

Review 1.  Mechanisms regulating chemokine receptor activity.

Authors:  Laura D Bennett; James M Fox; Nathalie Signoret
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

2.  On the origin of the triplet puzzle of homologies in receptor heteromers: immunoglobulin triplets in different types of receptors.

Authors:  Alexander O Tarakanov; Kjell G Fuxe; Dasiel O Borroto-Escuela
Journal:  J Mol Neurosci       Date:  2011-09-20       Impact factor: 3.444

3.  Far from the heart: Receptor cross-talk in remote conditioning.

Authors:  Christian Weber
Journal:  Nat Med       Date:  2010-07       Impact factor: 53.440

Review 4.  Chemokines: integrators of pain and inflammation.

Authors:  Fletcher A White; Sonia K Bhangoo; Richard J Miller
Journal:  Nat Rev Drug Discov       Date:  2005-10       Impact factor: 84.694

Review 5.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

Review 6.  Modulation of chemokine receptor activity through dimerization and crosstalk.

Authors:  C L Salanga; M O'Hayre; T Handel
Journal:  Cell Mol Life Sci       Date:  2009-04       Impact factor: 9.261

Review 7.  Membrane functional organisation and dynamic of mu-opioid receptors.

Authors:  André Lopez; Laurence Salomé
Journal:  Cell Mol Life Sci       Date:  2009-03-20       Impact factor: 9.261

8.  Triplet puzzle: homologies of receptor heteromers.

Authors:  Alexander O Tarakanov; Kjell G Fuxe
Journal:  J Mol Neurosci       Date:  2009-12-04       Impact factor: 3.444

9.  Autoantibodies to the delta-opioid receptor function as opioid agonists and display immunomodulatory activity.

Authors:  Parvathi Ranganathan; Hao Chen; Miranda K Adelman; Samuel F Schluter
Journal:  J Neuroimmunol       Date:  2009-10-30       Impact factor: 3.478

10.  The triplet puzzle theory indicates extensive formation of heteromers between opioid and chemokine receptor subtypes.

Authors:  Alexander O Tarakanov; Kjell Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2015-07-02       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.